Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, ON, Canada (G.L.H., G.K., M.M.S.).
Institute for Clinical Evaluative Sciences, Ottawa, Canada (H.I., M.M.S.).
Hypertension. 2022 Jan;79(1):178-186. doi: 10.1161/HYPERTENSIONAHA.121.18118. Epub 2021 Oct 18.
Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at the population level remains unknown. We performed a population-based retrospective cohort study of adults ≥18 years old in Ontario, Canada, with hypertension plus hypokalemia (potassium <3.5 mEq/L) from 2009 to 2015 with follow-up through 2017. We measured the proportion of individuals who underwent primary aldosteronism screening via the aldosterone-to-renin ratio based upon hypokalemia frequency and severity along with concurrent antihypertensive medication use. We assessed clinical predictors associated with screening via Cox regression. The cohort included 26 533 adults of which only 422 (1.6%) underwent primary aldosteronism screening. When assessed by number of instances of hypokalemia over a 2-year time window, the proportion of eligible patients who were screened increased only modestly from 1.0% (158/15 983) with one instance to 4.8% (71/1494) with ≥5 instances. Among individuals with severe hypokalemia (potassium <3.0 mEq/L), only 3.9% (58/1422) were screened. Among older adults prescribed ≥4 antihypertensive medications, only 1.0% were screened. Subspecialty care with endocrinology (hazard ratio [HR], 1.52 [95% CI, 1.10-2.09]), nephrology (HR, 1.43 [95% CI, 1.07-1.91]), and cardiology (HR, 1.39 [95% CI, 1.14-1.70]) were associated with an increased likelihood of screening, whereas age (HR, 0.95 [95% CI, 0.94-0.96]) and diabetes (HR, 0.66 [95% CI, 0.50-0.89]) were inversely associated with screening. In conclusion, population-level uptake of guideline recommendations for primary aldosteronism screening is exceedingly low. Increased education and awareness are critical to bridge this gap.
原发性醛固酮增多症是一种常见但高度未被诊断的高血压病因,可导致心血管疾病的发病率异常升高。高血压合并低血钾是指南推荐筛查原发性醛固酮增多症的指征,但在人群层面上,该建议的采纳率仍不清楚。我们在加拿大安大略省进行了一项基于人群的回顾性队列研究,纳入了 2009 年至 2015 年期间患有高血压合并低血钾(血钾<3.5mEq/L)且随访至 2017 年的年龄≥18 岁的成年人。我们根据低血钾的频率和严重程度以及同时使用的降压药物,通过醛固酮与肾素比值来衡量接受原发性醛固酮增多症筛查的个体比例。我们通过 Cox 回归评估与筛查相关的临床预测因素。该队列包括 26533 名成年人,其中只有 422 人(1.6%)接受了原发性醛固酮增多症筛查。在 2 年的时间窗口内,根据低血钾的次数评估,符合筛查条件的患者比例仅略有增加,从 1 次时的 1.0%(158/15983)增加到 5 次时的 4.8%(71/1494)。在严重低血钾(血钾<3.0mEq/L)患者中,仅有 3.9%(58/1422)接受了筛查。在服用≥4 种降压药物的老年人中,仅有 1.0%接受了筛查。接受内分泌科(危险比[HR],1.52[95%CI,1.10-2.09])、肾病科(HR,1.43[95%CI,1.07-1.91])和心内科(HR,1.39[95%CI,1.14-1.70])专业治疗与筛查的可能性增加相关,而年龄(HR,0.95[95%CI,0.94-0.96])和糖尿病(HR,0.66[95%CI,0.50-0.89])与筛查呈负相关。总之,人群层面上原发性醛固酮增多症筛查指南建议的采纳率极低。增加教育和认识对于缩小这一差距至关重要。